AC Immune SA is a prominent Swiss-based biopharmaceutical company engaged in the clinical development of innovative therapies primarily for neurodegenerative diseases. These diseases include Alzheimers disease, Parkinsons disease, and Down syndrome, with a particular focus on the underlying pathophysiological mechanisms that involve amyloid and tau proteins.
Segments
1. Research & Development (R&D): The R&D segment stands at the core of AC Immunes mission, driving the discovery and development of novel therapeutic candidates. This segment focuses on:
- Drug Candidates Development: The identification and optimization of new drug candidates aimed at addressing neurodegenerative diseases. - Target Identification: Research efforts to uncover new biological targets, enhancing the potential for future treatments. - Innovation & Technology Utilization: Utilizing advanced technologies such as machine learning and in silico modeling to expedite the drug discovery process.
2. Corporate: This segment encompasses the operational and strategic aspects of the company, including:
- Finance and Administration: Managing financial resources to ensure sustainability and operational efficiency. - Business Development: Cultivating partnerships with other biopharmaceutical companies and academic institutions, as well as negotiating licensing agreements to enhance research efforts and product pipelines. - Regulatory Affairs: Ensuring that the companys products comply with regulatory standards throughout the development process.
Products
AC Immune has a sophisticated pipeline of products that are at various stages of development, each designed to target specific proteins implicated in neurodegenerative diseases:
1. Crenezumab: A humanized monoclonal antibody targeting beta-amyloid plaques in Alzheimers disease. It aims to prevent or slow progression by neutralizing the toxic effects of aggregated beta-amyloid.
2. TauRx: A therapeutic small molecule targeting tau protein, which is critical in the formation of neurofibrillary tangles associated with Alzheimers disease. It focuses on preventing tau aggregation and promoting normal tau function.
3. ACI-24: A vaccine that targets beta-amyloid, currently in clinical trials. This vaccine is designed to elicit an immune response to beta-amyloid, potentially clearing plaques from the brain and slowing disease progression.
4. ACI-35: Another vaccine targeting tau protein, currently in preclinical development. This product aims to generate an immune response that could prevent tau aggregation and pathological effects.
5. Morphomer: A small molecule that specifically targets alpha-synuclein, a protein particularly relevant in Parkinsons disease, which is associated with the formation of Lewy bodies. It is in preclinical development and has the potential to modify the course of Parkinson’s disease.
Services
In addition to its product development, AC Immune offers a range of services that support drug development across the therapeutic landscape:
1. Drug Discovery: Utilizing high-throughput screening, advanced in vitro assays, and sophisticated animal models to identify and optimize potential drug candidates.
2. Preclinical Development: Conducting rigorous testing in preclinical models to assess the safety and efficacy of drug candidates before moving to clinical trials.
3. Clinical Development: Engaging in systematic clinical trials to evaluate the safety, tolerability, and therapeutic efficacy of drug candidates in human subjects.
4. Manufacturing: Overseeing the production of drug candidates to ensure a high-quality supply for clinical trials and eventual commercial distribution.
5. Business Development Services: Focused on exploring and establishing strategic alliances and partnerships to enhance the company’s pipeline and expand its market reach.
Conclusion
Overall, AC Immune SA stands out as a pioneering entity in the biopharmaceutical industry, dedicated to advancing the understanding and treatment of neurodegenerative diseases. Through extensive R&D efforts and a robust product pipeline, the company is positioned to make significant contributions to the field, particularly in the therapeutic targeting of amyloid and tau proteins.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
